Table 2.
Demographics, comorbidities, region of infection and outcomes in patients with NF
| LRINEC <6 (45%) | LRINEC ≥6 (55%) | P | |
|---|---|---|---|
| Age, years (mean ± SD) | 48 ± 15 | 53 ± 16 | 0.009 |
| Males (%) | 74 | 73 | 0.82 |
| Diabetes Mellitus (%) | 41.5 | 61.4 | 0.001 |
| Kidney disease % | 10 | 20 | 0.02 |
| Hypertension% | 28 (21.5) | 74 (46.8) | 0.001 |
| Site of infection % | |||
| Lower limbs | 49 | 55 | 0.32 |
| Perineum & genitalia | 35.3 | 34.8 | 0.92 |
| Abdominal and groin | 12.0 | 8.7 | 0.34 |
| Chest & breast | 3.0 | 2.5 | 0.78 |
| Face & neck | 6.0 | 7.5 | 0.62 |
| Number of debridement | 2.14 ± 1.5 | 2.09 ± 1.3 | 0.81 |
| Number of antibiotics useda (%) | |||
| ≤2 | 81 (78.6) | 83 (56.8) | 0.001 for all |
| >2 | 22 (21.4) | 63 (43.2) | |
| Hospital LOS; days | 11 (2–115) | 22 (2–129) | 0.001 |
| intensive care LOS; days | 5 (2–34) | 7 (1–75) | 0.01 |
| Septic shock (%) | 15 | 37 | 0.001 |
| Mortality (%) | 15 | 28.8 | 0.005 |
aFrequently used antibiotics are Tazocin, Clindamycin, Meropenem and Agumentin